about
Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care.Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.Targeting key proximal drivers of type 2 inflammation in disease.Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system.The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.Management and treatment of chronic urticaria (CU).Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
P2860
Q35865960-DCEFC0A8-77D3-49E6-B17E-232481B75B71Q36599623-FC6C24F9-77B4-4E4A-BDF4-FB7D235DFFE2Q36933639-03E900D5-6C24-4B94-A279-D682F3B90B35Q38608260-3E85546B-38AB-4A70-A5D4-96F71C32DBC6Q42782603-D42B93BC-3C42-4754-8DE3-B34F5BFE274DQ48104058-03E4B392-DF23-4D97-811C-30A6FC87DED1Q52938044-3CA79EE7-9090-4115-8830-C531E602DD22Q53733505-2B51BE65-0EF8-4205-A39E-54FAC1B4BE5D
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Omalizumab for the treatment of chronic urticaria.
@en
type
label
Omalizumab for the treatment of chronic urticaria.
@en
prefLabel
Omalizumab for the treatment of chronic urticaria.
@en
P2860
P1476
Omalizumab for the treatment of chronic urticaria.
@en
P2093
Marcus Maurer
P2860
P304
P356
10.1586/1744666X.2015.993971
P577
2015-01-07T00:00:00Z